Close Menu

NEW YORK – Epic Sciences and Predicine said Thursday that they have entered into a global strategic partnership to offer biopharmaceutical companies access to liquid biopsy testing via both Predicine's circulating tumor DNA technology and Epic's circulating tumor cell platform.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.